TaperCommunity
Depersonalization during withdrawal is one of the more frightening symptoms people encounter when tapering or stopping psychiatric medications. You look in the mirror and feel like a stranger is looking back. You watch yourself move through a room as if from a distance. The world looks flat, washed out, or like a film set. None of it feels quite real. For people who have never experienced it before, it can trigger significant alarm. Understanding what is happening neurologically, and why it is temporary for most people, makes an enormous difference in how you navigate it.
Depersonalization refers to the feeling of being detached from your own mind, body, or sense of self. You feel like an outside observer of your own thoughts, feelings, and actions. Derealization, which frequently accompanies it, is the sense that the external world looks unreal, dreamlike, or distorted.
These two experiences are distinct but often occur together, which is why clinicians group them under the term depersonalization-derealization disorder when they become chronic and distressing. During withdrawal, they almost always appear as transient symptoms rather than a new disorder.
The experiences themselves are not inherently dangerous. They are perceptual disruptions, not psychosis. You are not losing contact with reality in the way that word is typically used. You know the world is real. The strangeness is in how it feels, not in what you believe. That distinction is clinically meaningful and worth holding onto.
Estimates of how common this is during psychiatric medication withdrawal are hard to pin down, but among people tapering antidepressants and benzodiazepines, reports of depersonalization and derealization are frequent enough that they appear consistently in survey data from withdrawal communities and in published case literature.
To understand why withdrawal produces depersonalization, it helps to understand what these medications are doing to the brain in the first place.
Lexapro, Effexor, and other SSRIs and SNRIs upregulate serotonin availability at synapses. Over time, the brain adapts by downregulating certain serotonin receptor populations, particularly 5-HT2A receptors, which play a significant role in sensory integration and the coherent sense of self. When the medication is removed, these receptor populations and signaling pathways need time to recalibrate. During that recalibration period, the brain's ability to construct a stable first-person experience is temporarily compromised.
Benzodiazepines like Klonopin work through a different mechanism, enhancing GABA-A receptor function, but they produce similar perceptual disruptions on withdrawal. GABA is the brain's primary inhibitory neurotransmitter, and the GABAergic system plays a key role in regulating sensory gating. When that system is dysregulated after long-term benzodiazepine use, sensory input can feel destabilizing in ways that contribute to derealization.
The Maudsley Prescribing Guidelines note that abrupt discontinuation dramatically increases the likelihood of protracted neurological symptoms compared with gradual tapering, and perceptual symptoms like depersonalization are specifically listed among those most likely to persist when discontinuation is too rapid. This is part of the evidence base for hyperbolic tapering schedules, which reduce dose in smaller and smaller steps as the dose gets lower.
The felt sense of being a continuous self is not a fixed property of the brain. It is actively constructed, moment to moment, by a network of regions including the default mode network, the insular cortex, and the temporoparietal junction. These regions integrate signals from the body, from memory, and from sensory perception into a coherent narrative of "me, here, now."
Serotonin and GABA modulate this integration network heavily. When either system is in flux, the assembly of that coherent self-narrative becomes unreliable. The experience that results is exactly what people describe: a sense that the "I" has become ghostlike, that the body belongs to someone else, or that familiar environments look like photographs of themselves.
Research by Horowitz and Taylor, published in Lancet Psychiatry in 2019, identified that psychiatric drug effects and withdrawal effects are pharmacologically dose-dependent in a nonlinear way. This nonlinearity helps explain why the last few milligrams of a taper are often the hardest neurologically. The receptor occupancy changes are largest in proportion at low doses, meaning even small absolute dose reductions can produce large functional changes in these integrative brain networks.
The important takeaway is that depersonalization during withdrawal is not random. It has a mechanistic explanation. The brain is doing something specific, and it will, for the large majority of people, find its way back to stable integration over time.
Duration varies widely depending on how long the medication was taken, how it was discontinued, the person's neurological history, and factors that are not yet well understood.
For people who tapered gradually, depersonalization often appears as a wave during or shortly after dose reductions and resolves within days to a few weeks. For people who stopped abruptly or tapered too quickly, it can persist for months. In a smaller subset, particularly among long-term benzodiazepine users or those who experienced abrupt cold-turkey discontinuation from high-dose antidepressants, the symptom can be part of a protracted withdrawal syndrome that lasts longer.
The key pattern most people notice is that symptoms come in waves rather than remaining constant. A particularly bad day or week is usually followed by a window of relief. These windows tend to get longer and the waves shorter as the nervous system stabilizes. Tracking this pattern, even informally, helps enormously in reducing the fear response that can amplify the experience.
What reliably extends the duration is re-exposure and re-discontinuation cycles. Stopping a medication, reinstating due to severe symptoms, and stopping again tends to sensitize the withdrawal process. Slow and steady tapering, from the beginning, is the most reliable way to minimize both the severity and duration of perceptual symptoms.
Depersonalization-derealization disorder is a recognized psychiatric condition with a prevalence around 1-2% of the general population. Transient depersonalization episodes are considerably more common and can occur in the context of anxiety, panic disorder, PTSD, sleep deprivation, and cannabis use, among other triggers.
When you are in the middle of a medication taper, it can be difficult to know whether depersonalization is a withdrawal symptom or a re-emergence of a pre-existing condition. A few questions help clarify this.
Did you experience depersonalization before ever taking the medication? If yes, the withdrawal period may be unmasking or worsening something that was already present. If no, and if the onset correlates clearly with a dose reduction or discontinuation, withdrawal is the more parsimonious explanation.
Is the depersonalization accompanied by other recognized withdrawal symptoms, such as brain zaps, temperature dysregulation, sleep disruption, or mood volatility? When it travels with this cluster, the withdrawal explanation is stronger.
Is it getting worse over time or following the wave-and-window pattern? Gradual worsening over months without any windows of relief warrants clinical evaluation regardless of cause. Intermittent improvement is more consistent with withdrawal.
Bringing this timeline to a clinician, in writing if needed, can help them distinguish the two possibilities and inform the management plan.
No medication reliably eliminates withdrawal-induced depersonalization, and adding new medications to a destabilized nervous system often complicates rather than resolves the situation. What helps tends to be less pharmacological.
Grounding practices are well-established for managing acute episodes. The mechanism is straightforward: they shift attention away from the metacognitive loop of observing yourself feel unreal, and toward concrete sensory input. Holding ice, running cold water over the hands, or paying close attention to the physical sensations of walking all engage the insular cortex with real-time body data, which counteracts the dissociative drift.
Regulating the nervous system through consistent sleep, gentle movement, and limiting stimulant intake reduces the overall load on the integrative networks that are already under strain. Alcohol and cannabis are worth noting specifically. Both can temporarily worsen depersonalization and derealization, and cannabis in particular can induce severe, prolonged episodes in people whose perceptual systems are already dysregulated.
Reducing the fear response around the symptom itself makes a meaningful difference in how long episodes last. Depersonalization is not dangerous, and fighting it or panicking about it tends to increase its intensity. Accepting that you feel strange, without interpreting that strangeness as catastrophic, is both a skill and a process. It takes practice but it works.
Slowing or pausing the taper is sometimes necessary if depersonalization is severe enough to interfere with functioning. Reinstating to the previous dose or stabilizing at the current dose before continuing is not failure. It is appropriate pacing based on the nervous system's actual tolerance.
Withdrawal-induced depersonalization is rarely a psychiatric emergency, but there are situations that warrant prompt evaluation.
If you cannot distinguish the experience from psychosis, meaning you are genuinely uncertain whether the world is real or not, rather than feeling that it seems unreal while knowing it is, seek evaluation. If depersonalization is accompanied by suicidal thoughts, disorientation severe enough to affect safety, or an inability to care for yourself, these are urgent presentations regardless of their cause.
Protracted withdrawal symptoms that do not show any improvement after several months also warrant evaluation, both to rule out other causes and to explore whether there are adjunct supports that could help stabilize the process.
Depersonalization during withdrawal is a temporary disruption in how the brain integrates sensory and self-referential information. It has a mechanistic explanation, it follows recognizable patterns, and it resolves for most people who are tapering carefully. The experience is distressing, but it is not a sign that something permanent has gone wrong.
If you are navigating this and want to connect with people who have been through it, taper.community is a space for exactly that. Members share what has and has not helped, and there is something genuinely useful in hearing from people who understand the experience from the inside.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your medication regimen.